SAN DIEGO, Feb. 5, 2018 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces the issuance of patents in Europe, Japan
and Hong Kong for its core Target
Selector™ liquid biopsy technology. In Japan, Biocept's patent no. 6234817 is
entitled METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION, and in
Europe, Biocept's patent no.
2995953 is entitled DEVICES AND METHODS OF CELL CAPTURE AND
ANALYSIS. In Hong Kong, Biocept's
patent no. HK1191043 is entitled CELL SEPARATION USING MICROCHANNEL
HAVING PATTERNED POSTS. All of these patents are directed to the
capture and analysis of rare cells of interest, such as cancer
cells, that are shed into the blood from solid tumors. Biocept now
has 25 issued patents globally for its liquid biopsy technology
platforms.
"The granting of these patents further expands Biocept's
intellectual property rights regarding the use of antibody
'cocktails' and separately microfluidic devices to capture and
interrogate rare cells of interest from any sample type," said
Lyle Arnold, Ph.D., Chief Scientific
Officer at Biocept. "Expansion of our patent rights worldwide
further establishes Biocept's proprietary position in the liquid
biopsy segment."
Michael Nall, Biocept's President
and CEO, added, "Expanding Biocept's patent protection around the
world is an important component of our strategy and these newly
issued patents strengthen the opportunity to develop business in
major markets outside the U.S. We now have 25 issued patents for
our core technologies and we intend to continue to broaden and
leverage our intellectual property position throughout the
year."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company leverages its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. Biocept's patented Target
Selector™ liquid biopsy technology platforms capture and analyze
tumor-associated molecular markers on circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are
based upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend" or
"project," or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this news release are not strictly historical,
including, without limitation, statements as to our ability to
improve the outcomes of cancer patients, the utility and
effectiveness of our intellectual property protections, our ability
to broaden and leverage our intellectual property in the future,
the perceived benefits of our proprietary liquid biopsy technology,
and our ability to develop business outside the U.S., such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this news release. We
do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in
this press release except as required by law. Readers are advised
to review our filings with the SEC at www.sec.gov
View original content with
multimedia:http://www.prnewswire.com/news-releases/biocept-receives-additional-patent-issuances-in-three-major-international-territories-for-its-target-selector-platform-300592847.html
SOURCE Biocept, Inc.